Evidence check: CYP1A2 in the context of Haut

CYP1A2 is a phase I metabolic enzyme primarily expressed in the liver, responsible for metabolizing caffeine, certain drugs, and some procarcinogens. In the skin, CYP1A2 expression is low; cutaneous CYP1A1 and CYP1B1 are more relevant. Evidence linking CYP1A2 variants (e.g., rs762762, the *1F allele) directly to skin health is weak and mostly indirect. Some studies suggest that caffeine intake – whose clearance is influenced by CYP1A2 activity – may be associated with a reduced risk of basal cell carcinoma, but findings are inconsistent. Other research explores CYP1A2 in the context of UV damage or acne without clear clinical significance. Most data come from mechanistic or epidemiological studies, not RCTs. A consumer DNA test for CYP1A2 can indicate personal caffeine metabolism, but extrapolating to skin conditions is not evidence-based. Users should understand that such tests do not diagnose or guide treatment for skin issues. The evidence level is best described as 'mechanistic' or 'mixed'.